Dopaminergic neurons regulate and organize numerous important behavioral processes including motor activity. Consistently, manipulation of brain dopamine concentrations changes animal activity levels. Dopamine is synthesized by several neuronal populations in the brain. This study was carried out to directly test whether selective activation of dopamine neurons in the midbrain induces hyperactivity. A pharmacogenetic approach was used to activate midbrain dopamine neurons, and behavioral assays were conducted to determine the effects on mouse activity levels. Transgenic expression of the evolved hM3Dq receptor was achieved by infusing Creinducible AAV viral vectors into the midbrain of DATCre mice. Neurons were excited by injecting the hM3Dq ligand clozapine-N-oxide (CNO). Mouse locomotor activity was measured in an open field. The results showed that CNO selectively activated midbrain dopaminergic neurons and induced hyperactivity in a dose-dependent manner, supporting the idea that these neurons play an important role in regulating motor activity.
INTRODUCTION
As an important neurotransmitter, dopamine is believed to modulate neuronal excitability and neurotransmission in numerous brain areas [1] . It is synthesized by a subset of neurons in the ventral tegmental area, the substantia nigra pars compacta (VTA/SNc) of the midbrain, as well as in the hypothalamus and olfactory bulb [2] . Midbrain dopaminergic neurons project axons extensively to the cortex and striatum and their activity is believed to be closely related to fundamental behavioral processes such as cognition, motor activity, and reward [2, 3] . The dopaminergic projection from the VTA/SNc to the neostriatum in the basal ganglia is believed to be particularly critical for motor control [2] .
Several lines of evidence suggest that brain dopamine signals are closely associated with the regulation of motor activity. Acute administration of drugs such as amphetamine and cocaine increases brain dopamine levels, leading to striking hyperactivity in animals and humans [4, 5] . Genetic manipulations that change brain dopamine levels also alter motor activity levels [5, 6] . In humans, malfunctions of the brain dopamine system are associated with several neurological and neuropsychiatric disorders with the disruption of motor activity as one of the core symptoms [7, 8] . However, the conclusions of these studies are often confounded by drug effects on targets outside the dopamine system, or potential disruption of neural circuits during development after gene knockout. Whether increasing the activity of midbrain dopaminergic neurons induces hyperactivity remains to be directly tested. 518 relatively large area of the midbrain [2] . In this study, we tested whether the activation of midbrain dopaminergic neurons affects motor activity with a pharmacogenetic tool [9, 10] . The gene encoding the evolved hM3Dq receptor was targeted into midbrain dopaminergic neurons by stereotaxic injection of a Cre-inducible AAV viral vector [11, 12] . Dopaminergic neurons were then remotely excited by intraperitoneal injection of the hM3Dq ligand clozapine-Noxide (CNO). We found that selective pharmacogenetic activation induced a dramatic increase in mouse motor activity, directly supporting a role for midbrain dopaminergic neurons in hyperactivity.
MATERIALS AND METHODS

Mice
Animal protocols were approved by the institutional Animal 
AAV Viral Vectors for hM3Dq and mCherry
We used Cre-dependent AAV vectors with two pairs of loxP recombination sites covering the specific genes in a 3'-to-5' orientation (AAV DIO) [12] . The inverted coding sequence of hM3Dq-2A-mCherry or mCherry was placed into an AAV DIO vector with a CMV early enhancer/chicken β-actin (CAG) promoter (Fig. 1A, B) . The vectors were then packaged in AAV serotype 2/9 vectors consisting of the AAV2 ITR genomes and the AAV9 serotype capsid gene. The AAV2/9 viral vectors were produced in HEK293 cells by the 3-plasmid transfection method and purifi ed by cesium chloride density-gradient centrifugation and then desalination by dialysis [13] , producing AAV viral vector titers of >10 12 particles/mL.
Stereotaxic Virus Injection
Mice were anesthetized with pentobarbital (80 mg/kg; i.p.). and processed with Adobe Photoshop.
Circadian Locomotor Activity
Circadian global activity was assessed by measuring the daily locomotor activity (24 h) in a test cage (30 cm × 30 cm) with an overhead infrared camera. Each animal was fi rst habituated to the test cage for 24 h. Saline or CNO (1.0 mg/kg) was then injected at the onset of the dark phase of the second and third days before monitoring locomotor activity.
Open-Field Test
We used the open-fi eld test to investigate the effect of CNO on locomotor activity. In this test, an individual mouse was 
Statistical Analysis
All data are presented as mean  SEM. Data analysis was performed with Matlab (MathWorks). T-test and ANOVA were performed to determine the significance of variable contributions and P <0.05 was considered as statistically signifi cant.
RESULTS
Selective Activation of Midbrain Dopaminergic Neurons
We used Designer Receptors Exclusively Activated by Designer Drugs (DREADD) technology to selectively excite midbrain dopaminergic neurons. AAV viral vectors were bilaterally injected into the VTA/SNC areas of DAT-Cre mice to express the evolved human muscarinic receptor hM3Dq, which is activated by its ligand CNO but not endogenous neurotransmitters [10] . The coding sequence of were also TH-immunopositive (Fig. 1D) . These results thus demonstrated that the application of Cre-dependent AAV virus produces effi cient and selective expression of hM3Dq/ mCherry in midbrain dopaminergic neurons.
To determine whether CNO excites midbrain dopaminergic neurons, we fi rst carried out target recordings from hM3Dq/mCherry + dopaminergic neurons in brain slices (n = 6 cells). Cell-attached recordings showed that pressure-injection of CNO (10 μmol/L) elicited vigorous firing of action potentials ( Fig. 2A) . Whole-cell currentclamp recordings demonstrated that CNO depolarized these neurons and evoked action-potential fi ring (Fig. 2B) . online for 24 h. Horizontal travel distance was used as the index of activity levels. In hM3Dq-expressing mice, the activity was immediately elevated after CNO injection but not saline. A more than eight-fold increase was induced during the fi rst hour after drug injection (Fig. 3) . In contrast, CNO at 0.5 mg/kg increased the activity levels of hM3Dq-expressing mice (P <0.001; paired t-test between saline and CNO; n = 12 mice) but not mCherry-expressing mice (P = 0.59; paired t-test between saline and CNO; n = 12 mCherry-expressing mice) (Fig. 4A-C) . The activity levels (Fig. 4D) . Our results confirm and extend our understanding of the relationship between the dopaminergic system and the regulation of motor activity. High levels of dopamine are believed to induce hyperactivity [4, 5] . However, previous studies did not establish a direct link between the activity of midbrain dopaminergic neurons and hyperactivity.
The interpretation of drug-induced behavioral changes is commonly challenged by the presence of multiple populations of dopaminergic neurons within and outside the midbrain VTA/SNc area as well as by the effects of drugs on targets not directly related to dopamine signaling.
Hyperactivity is manifested by hyperdopaminergic mutant mice, including dopamine transporter (DAT) knockout mice [5, 6] and DAT knockdown mice [14] . Genetic knockout or knockdown of DATs increases dopamine levels inside and outside the nervous system and may change neural circuit formation during development. Our study benefits from the advantages of pharmacogenetic approaches, which allow acute, reversible, and selective activation of a given set of neurons. In addition, viral transgenic expression of the hM3Dq receptor bypasses the possibility of developmental change that might be associated with genetic manipulations.
Interestingly, hyperactivity can be induced by both increasing and decreasing brain dopamine levels. Human brain imaging and animal studies have strongly suggested that a hypofunctional dopamine system underlies the core symptoms of attention deficit/hyperactivity disorder (ADHD) [15] [16] [17] [18] . The low-dopamine theory explains why low levels of stimulant drugs mildly increase brain dopamine levels but paradoxically reduce the hyperactivity in human ADHD. Nevertheless, the increase of activity in lowdopamine-related ADHD is substantially milder than that evoked by the selective activation of midbrain dopaminergic neurons. Rodent models of ADHD exhibit about a onefold increase in locomotor activity [15, 19] . In contrast, a nearly ten-fold increase can be induced by increasing dopamine levels with drugs [5, 6] . This drastic hyperactivity evoked by pharmacogenetic activation might be more appropriately considered as a symptom of the mania-like behavior associated with high-dopamine [5, 6] but not ADHD associated with low-dopamine [15, 19] .
Our study demonstrated the effectiveness of areas. Moreover, they do not require the implantation of optic fi bers and provide a more convenient way to monitor animal behavior. Since the midbrain dopaminergic system is involved in a diverse array of cognitive processes [2, 3] , pharmacogenetic methods can be used to study the effects of activating dopaminergic neurons on animal performance in other behavioral tests, such as conditioned place preference, drug self-administration, and operant conditioning.
